LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Akcijų sąrašas・Innoviva Inc

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

22.13 -2.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.05

Max

22.85

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-55M 187M
Pardavimai	-20M 98M
P/E Sektoriaus vid.	3.588 50.102
Pelnas, tenkantis vienai akcijai	0.47
Pelno marža	190.415
Darbuotojai	159
EBITDA	-160M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+52.12% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-45M 1.7B
Ankstesnė atidarymo kaina	24.3
Ankstesnė uždarymo kaina	22.13

Naujienos nuotaikos

By Acuity

63%

37%

284 / 344 reitingas Healthcare

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-27 21:33; UTC

Uždarbis

Correction to Salesforce 1Q Sales, Profit Rise Article

2026-05-27 21:00; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Agrees to Buy The College of Health Care Professions

2026-05-27 20:18; UTC

Uždarbis

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

2026-05-27 23:49; UTC

Rinkos pokalbiai

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

2026-05-27 23:39; UTC

Rinkos pokalbiai

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

2026-05-27 23:34; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-27 23:08; UTC

Rinkos pokalbiai

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

2026-05-27 22:21; UTC

Rinkos pokalbiai

Salesforce Lays Out AI Monetization Strategy -- Market Talk

2026-05-27 21:29; UTC

Karštos akcijos

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

2026-05-27 21:08; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

2026-05-27 21:02; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

2026-05-27 20:59; UTC

Įsigijimai, susijungimai, perėmimai

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

2026-05-27 20:55; UTC

Uždarbis

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

2026-05-27 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-27 20:48; UTC

Uždarbis

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

2026-05-27 20:45; UTC

Uždarbis

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

2026-05-27 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Webster Financial Stockholders Approve Sale to Banco Santander

2026-05-27 20:32; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

2026-05-27 20:32; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

2026-05-27 20:30; UTC

Uždarbis

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

2026-05-27 20:30; UTC

Įsigijimai, susijungimai, perėmimai

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

2026-05-27 20:22; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:16; UTC

Uždarbis

Salesforce Stock Slides on Mixed Results -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

2026-05-27 20:13; UTC

Uždarbis

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

2026-05-27 20:13; UTC

Uždarbis

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

2026-05-27 20:12; UTC

Uždarbis

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

52.12% į viršų

12 mėnesių prognozė

Vidutinis 34.5 USD 52.12%

Aukščiausias 46 USD

Žemiausias 18 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Innoviva Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

284 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.